Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Modify Date: 2024-03-26 15:44:58

Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo- structure	Common Name	Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-
	CAS Number	23623-31-6	Molecular Weight	459.53200
	Density	1.23g/cm3	Boiling Point	N/A
	Molecular Formula	C₂₅H₃₃NO₇	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2].

Name	Lankacidin C
Synonym	More Synonyms

Description	Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vivo	Lankacidin C (75-1000 mg/kg；腹腔注射；一天一次持续 5 天) 以剂量依赖性方式延长了 (C57BL/6×DBA/2) F1 (BDF1) 小鼠的平均生存时间。Lankacidin C (1000 mg/kg) 在植入 B-16 黑色素瘤的 C57BL/6 小鼠中显著抑制了 B-16 黑色素瘤的生长[2]。 Lankacidin C (300 mg/kg；腹腔注射；一天一次持续 6 天) 在含有L-1210/6-巯基嘌呤或 L-1210/阿糖胞苷的 BDF1 小鼠中，抑制对 6-巯基嘌呤 (6-Mercaptopurine，HY-13677) 或阿糖胞苷 (Cytosine Arabinoside，HY-13605) 耐药的 L-1210 细胞活性[2]。 Lankacidin C (10-100 mg/kg；腹腔注射；一天一次持续 5 天) 显著延长了含有 6C3 HED/OG 或 6C3 HED/RG 淋巴肉瘤的 C3H/He 小鼠平均生存时间[2]。 Lankacidin C (500 mg/kg；腹腔注射；一天一次持续 3 或 4 天) 在抗原刺激前后抑制 ICR 小鼠抗绵羊红细胞抗体的产生[2]。 Animal Model: C57BL/6, C3H/He, ICR and (C57BL/6×DBA/2) F1 (BDF1) mice[2]. Dosage: 10, 20, 25, 30, 40, 50, 100, 150, 250, 300, 500, 600 or 1000 mg/kg Administration: Intraperitoneal injection; once daily for 3, 4, 5 or 6 days Result: Inhibited the growth of L1210 leukemia, B16 melanoma and 6C3 HED/OG or 6C3 HED/RG lymphosarcoma cells.
References	[1]. Cai L, et al. Modular Approaches to Lankacidin Antibiotics. J Am Chem Soc. 2020 Sep 2;142(35):15116-15126. [2]. Ootsu K, et al. Effects of Lankacidin group (T2636) antibiotics on the tumor growth and immune response against sheep erythrocytes in mice. Gan. 1973 Oct;64(5):481-92.

Density	1.23g/cm3
Molecular Formula	C₂₅H₃₃NO₇
Molecular Weight	459.53200
Exact Mass	459.22600
PSA	130.00000
LogP	2.10860
Index of Refraction	1.566

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UZ0780000

CHEMICAL NAME :: Pyruvamide, N-(7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-1 6-oxabicyclo(13.2.2) nonadeca-3,5,9,11-tetraen-2-yl)-, (all-E)-(1S,2R,7S,13S,15R,19R)-(-)-

CAS REGISTRY NUMBER :: 23623-31-6

LAST UPDATED :: 199112

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C25-H33-N-O7

MOLECULAR WEIGHT :: 459.59

WISWESSER LINE NOTATION :: T6-17- A B AOV DV IU KU OU QUTJ C1 E1 HQ K1 NQ Q1 SMVV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85FZAT "Index of Antibiotics from Actinomycetes," Umezawa, H. et al., eds., Tokyo, Univ. of Tokyo Press, 1967 Volume(issue)/page/year: -,184,1967

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968- Volume(issue)/page/year: 26,647,1973

Glycine-d5

CAS#:4896-77-9

Propanamide,N-[...

CAS#:23623-31-6

Propanamide,N-[...

CAS#:23477-98-7

Literature: Kakinuma, Katsumi; Uzawa, Jun; Uramoto, Masakazu Tetrahedron Letters, 1982 , vol. 23, # 50 p. 5303 - 5306

Precursor 1
CAS#:4896-77-9 Glycine-d5
DownStream 0

Bundlin A

(-)-lankacidin C

Antibiotic T-2636C

N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-Dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide

lankacidins

Lankacidin

Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Use of Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Names

Biological Activity

Chemical & Physical Properties

Toxicological Information

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

Synthetic Route

Precursor & DownStream

Synonyms